Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Results from 96 Weeks Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4

Author:Wang, Leo   Han, Jay   Shoskes, Jennifer   Jiang, John   Tawil, Alrabi   

Session Name:S48: Therapeutics for Muscle Disease  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S48.008  

Author Institution:University of Washington, Seattle, WA  UCI Medical Center, Orange, CA  Fulcrum Therapeutics, Cambridge, MA  University of Rochester Medical Center, Rochester, NY  

Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD

Author:Tawil, Alrabi   Han, Jay   Wang, Leo   Vissing, John   Statland, Jeffrey   Shoskes, Jennifer   Jiang, John   

Session Name:P6: Neuromuscular Disease: Inherited Muscle Disorders 3  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P6.007  

Author Institution:University of Rochester Medical Center, Rochester, NY  UCI Medical Center, Orange, CA  University of Washington, Seattle, WA  University of Copenhagen, Copenhagen, Denmark  University of Kansas Medical Center, Kansas City, KS  Fulcrum Therapeutics, Cambridge, MA